Merrimack Gets $77M Series G

Xconomy Boston — 

Cambridge, MA-based cancer drug developer Merrimack Pharmaceuticals said today that it has pinned down $77 million in Series G financing from new and existing backers. The money will go to advancing Merrimack’s pipeline of novel cancer therapies. The company’s investors include Credit Suisse First Boston Next Fund, Crocker Ventures, funds advised by Fred Alger Management, funds advised by Noonday Asset Management, Jennison Associates, TPG-Axon Capital, and WT Investment Advisors Fund.